

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) LiposomalPharmaceutical or veterinary formulations comprising at least one active hydrophilic agent encapsulated in liposomes composed of at least one lipid bilayer formed by a mixture of at least one neutral saturated phospholipid and at least one charged saturated lipid.
2. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, wherein the neutral saturated phospholipid is selected from the group consisting of derivatives of phosphatidylcholine and their combinations.
3. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 2, wherein the derivative of phosphatidylcholine is selected from the group consisting of DSPC, DPPC and DMPC.
4. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, wherein a negatively charged saturated lipid of said charged saturated lipid is selected from the group consisting of a group composed of derivatives of phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatidic acid and their combinations.
5. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 4, wherein the negatively charged saturated lipid is selected from the group consisting of DSPG, DPPG and PS.
6. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, wherein the positively charged saturated lipid of said charged saturated lipid is SA.

7. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1 ~~further~~further comprising at least one other lipid selected from the group consisting of sterols and derivatives, gangliosides and sphingomyelins.
8. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 7, wherein the sterol is cholesterol.
9. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to ~~claim 1~~claim 1, wherein the active hydrophilic agent is a drug.
10. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 9, wherein the drug has low molecular weight.
11. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 10, wherein the drug with low molecular weight is selected from amongst 5-fluorouracil, acyclovir, iododeoxyuridine, methotrexate and ciprofloxacin.
12. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, comprising 5-fluorouracil encapsulated in liposomes composed of DSPC:DSPG.
13. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, comprising 5-fluorouracil encapsulated in liposomes composed of DSPC:PS.
14. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, comprising acyclovir encapsulated in liposomes composed of DPPC:CHOL:DPPG.

15. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, comprising acyclovir encapsulated in liposomes composed of DSPC:DSPG.
16. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, wherein the bilayer lipid has a neutral saturated phospholipid/charged saturated lipid molar ratio between 50/50 and 95/5.
17. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 16, wherein the neutral saturated phospholipid/charged saturated lipid molar ratio is between 80/20 and 95/5.
18. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, wherein an active hydrophilic agent/lipids molar ratio is between 0.01/1 and 40/1.
19. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 18, wherein the active hydrophilic agent/ lipids molar ratio is between 0.1/1 and 2/1.
20. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1, wherein a 5-fluorouracil/ lipid molar ratio is between 0.2 and 1.5.
21. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 20, wherein the 5-fluorouracil/lipid molar ratio is between 0.5 and 1.0.
22. (Currently amended) LiposomalThe pharmaceutical or veterinary formulations according to claim 1 further including a pharmaceutically acceptable vehicle ~~thereby forming a pharmaceutical formulation.~~

23-28. (Cancelled)

29. (Withdrawn) A method to prepare a liposomal formulation, comprising:
combining at least one neutral saturated phospholipid and at least one charged saturated
lipid with at least one organic solvent in a container;
eliminating the solvent to form a lipid film on the walls of the container;
combining the lipid film with an aqueous solution of a hydrophilic active agent to form a
liposomal suspension; and
subjecting the liposomal suspension to diafiltration with a buffer solution.

30. (Withdrawn) The method of claim 29, further comprising extracting the liposomal
suspension through a filter to select the vesicular size after the step of combining to form the
liposomal suspension.

31. (Withdrawn) The method of claim 29, further comprising diluting the liposomal
suspension with a buffer solution after the step of subjecting.

32. (New) The pharmaceutical or veterinary formulations of claim 1 formulated for topical
administration.